New Two-Drug immune treatment aims to keep pancreatic cancer at bay
NCT ID NCT07199764
Summary
This study is testing whether a combination of two immunotherapy drugs can help control pancreatic cancer after initial chemotherapy. The treatment is given as maintenance therapy to patients whose cancer hasn't gotten worse after 4-6 months of standard chemotherapy. Researchers want to see if this approach can keep the cancer from progressing longer than usual care.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital of the University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.